Olumiant
Named-patient access overview. Olumiant is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Olumiant (baricitinib) is an oral selective Janus kinase (JAK1 and JAK2) inhibitor. It was approved by the US Food and Drug Administration in May 2018 for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies; the FDA approval expanded in June 2022 for severe alopecia areata in adults, and an emergency use authorisation followed by full approval covers hospitalised COVID-19 patients requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Olumiant
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Olumiant is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Olumiant in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Olumiant
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.